The UK Cystic Fibrosis Gene Therapy Consortium: About Us

About the UK Cystic Fibrosis Gene Therapy Consortium

The Consortium groups are based in three of the leading UK universities. Prior to the formation of the Consortium each group had conducted at least one clinical trial for gene therapy. Therefore, our researchers have been at the forefront of this field for over 20 years.

These sections describe the how the Consortium functions and how we are organised.

Together against CF

In 2001 the UK's three UK's three leading Cystic Fibrosis gene therapy groups joined together as one organisation, the UKCFGTC, to share expertise and funding.

Aim

The aim of this collaboration was to bring the three research groups together to focus on a single common goal of making gene therapy for CF a clinical reality.

Progress

The Consortium is now the world's largest gene therapy group focused on a single disease, with a combined staff of over 50. Our clinical trial programme is well underway and there are plans to initiate a multi-dose study of our first clinical product in 2012.

This multi-dose trial will be the first ever opportunity to find out if our gene therapy can result in clinical benefit.

Consortium Members

University of Oxford: Gene Medicine Group

University of Edinburgh: Centre for Molecular Medicine and Roslin Institute

Imperial College London: Department of Gene Therapy, National Heart & Lung Institute